BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Dow'. (Return)

MarketWatch MarketPulseOct 27, 2020
Cummins stock surges toward a record after profit and revenue beats, upbeat outlook
Shares of Cummins Inc. surged 4.2% toward a record high in premarket trading Tuesday, after the diesel, natural gas and electric engines maker reported third-quarter profit and sales that fell, but beat expectations, and provided an upbeat outlook. Net income declined to $501 million, or $3.36 a share, from $622 million, or $3.97 a share, in the year-ago period. The FactSet consensus for earnings per share was $2.42. Revenue declined 11.3% to $5.12 billion, but beat the FactSet consensus of $4.51 billion. Engine sales fell 13% to $2.1 billion to beat expectations of $1.71 billion; components sales were down 14% to $1.7 billion but topped expectations of $1.24 billion; and power systems sales declined 13% to $981 million, but topped forecasts of $794.5 million; while distribution sales slid 14% to $1.7 billion, just shy of expectations of $1.75 billion. The company said it expects fourth-quarter sales to be "similar" to third-quarter levels, which would be above the current FactSet consensus of $4.77 billion. Cummins said that on Oct. 1, it ended the temporary salary reductions that were implemented in April. The stock has rallied 15.6% over the past three months through Monday, while the S&P 500 has gained 5.0%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatch MarketPulseOct 27, 2020
Pfizer cites $500 million impact in the third quarter as a result of the COVID-19 pandemic
Shares of Pfizer Inc. were up 0.1% in premarket trading on Tuesday after the drug maker missed sales expectations for the quarter. Pfizer had earnings of $2.2 billion, or 39 cents per share, in the third quarter of 2020, down from $7.7 billion, or $1.36 per share, in the same quarter a year ago. It had adjusted earnings per share of 72 cents for the quarter, against a FactSet consensus of 71 cents. The drug company's revenue fell 4% to $12.1 billion for the quarter, compared with $12.7 billion in the same quarter a year ago. The FactSet consensus was $12.3 billion. The company attributed an estimated unfavorable impact of $500 million for the quarter to the COVID-19 pandemic, citing lower demand for anti-infective products used in surgeries in China and disruptions in traditional prescribing patterns in the U.S. as people avoided going to to the doctor, including a 19% drop in sales of its smoking-cessation drug Chantix. The impact was offset to some degree by "strong performance" of its heart drugs, Vyndaqel and Vyndamax, and its biosimilars business. It did not disclose any additional details about its work to develop a COVID-19 vaccine with BioNTech . However, it did note that the Phase 2/3 clinical trial for the vaccine candidate had enrolled 42,000 participants as of Monday, and about 85% of the participants have received their second and final dose of the experimental vaccine. Pfizer adjusted its 2020 guidance for adjusted earning share to $2.88 to $2.93, from $2.85 to $2.95. Pfizer's stock is down 3.2% for the year, compared with the S&P 500 , which has gained 5.2%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



CNBC BusinessOct 27, 2020
5 things to know before the stock market opens Tuesday
U.S. stock futures pared gains Tuesday, one day after the Dow led a huge down day on Wall Street.

Yahoo BusinessOct 27, 2020
Oppenheimer: These 3 Stocks Are Poised to Surge by at Least 60%
It's down to the wire. The U.S. Presidential elections are only a week away, and with the polls showing Biden has an edge over President Trump, investors are preparing.Oppenheimer's Chief Investment Strategist John Stoltzfus points out that last week, stocks churned as investors rebalanced their portfolios, rotating and adding additional exposure to value stocks "while others took profits in growth names that had previously run-up substantially ahead of what could be higher capital gains and other taxes next year," in the event that the Democrats come out on top.Highlighting that the expectation of an effective COVID-19 vaccine is behind the broadening of investor appetite for equities, Stoltzfus argues this renewed appetite " improves the attractiveness of value stocks."Going forward, the strategist notes the Federal Reserve's efforts "underscore the case for the economy's recovery and the equity markets' resilience and potential from here." Although a "blue wave" is seen as a potential risk, Stoltzfus thinks this outcome is very unlikely, and that continued split control should alleviate market worries.Taking Stoltzfus' outlook into consideration, our attention turned to three stocks Oppenheimer analysts believe can surge by at least 70% in the year ahead. Running the tickers through TipRanks' database, we found out that each boasts a "Strong Buy" consensus rating from the broader analyst community.Chromadex (CDXC)Focused on improving the way people age, Chromadex operates as a science-based integrated

Wall Street Journal US BusinessOct 27, 2020
Pandemic Dents Third-Quarter Sales for Pfizer
The Covid-19 pandemic weighed down sales for some drugs in the latest quarter as the company's candidate vaccine for the virus that has caused the public-health crisis continues in a large late-stage trial.

MarketWatch MarketPulseOct 27, 2020
Stocks rise at the open one day after Dow's worst day in 8 weeks
U.S. stocks opened modestly higher Tuesday one day after suffering their worst sell-off in weeks as the presidential election, and hoped-for fiscal aid, drew closer. The Dow Jones Industrial Average gained 16 points, 0.1%, to open near 27,701, while the S&P 500 was up 5 points or 0.2%, at 3,406. The Nasdaq Composite led, with a 50-point or 0.4% increase, opening near 11,409 . Shares of Harley-Davidson Inc. surged more than 11%in early trading after the motorcycle company reported third-quarter earnings and revenue that trounced forecasts. And on Tuesday the government said orders for durable goods rose 1.9% in September, marking the fifth-straight month of growth.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



The Motley FoolOct 27, 2020
Why Aurora Cannabis, Canopy Growth, and Tilray Stocks Were Down 5% (and More) on Monday
Last week's Election 2020 debate was a disappointment -- for cannabis fans.

RELATED ARTICLES
Crocs shares rise after 'record' earnings report (MarketWatch MarketPulse)
Harley-Davidson shares jump after earnings and revenue blow past expectations (MarketWatch MarketPulse)
3M's stock ticks up after profit beats expectations, sales rise just above forecasts (MarketWatch MarketPulse)
Google Business NewsOct 26, 2020
Dow Jones Futures: Stock Market Rally Struggles As Coronavirus Cases Soar; Dexcom, Twilio Are Key Movers Late - Investor's Business Daily
Dow Jones Futures: Stock Market Rally Struggles As Coronavirus Cases Soar; Dexcom, Twilio Are Key Movers Late  Investor's Business DailyDow drops 650 points as S&P 500, Nasdaq post worst day since September  Fox BusinessAsian shares slip after Wall St's worst day in a month  KTAR.comDow Slumps as Record Surge in Infection Triggers Bloodbath  Investing.comWall Street tumbles as virus cases soar  Reuters
TRENDING TAGS
stockmarket COVID-19 surge Cases profit
Stockssurge Covid-19 European My Cases
COVID-19cases stocks surge How European
earningsCall Transcript Q3 Inc shares
Coronaviruscases latest pandemic Dow high
Salesprofit expectations Pandemic Fall 3M
buybillion AMD Xilinx Stock Stocks
profitMy beats sales outlook expectations
pandemiccoronavirus How Sales amid During
ElectionDay How Stock Market one

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC